Improvement of liver function by the administration of oyster extract as a dietary supplement to habitual alcohol drinkers: A pilot study

Osaki,Kenji; Shimizu,Yoshio; Yamamoto,Tetsuro; Miyake,Fumiharu; Kondo,Sumio; Yamaguchi,Hideyo

doi:10.3892/etm.2015.2563

Improvement of liver function by the administration of oyster extract as a dietary supplement to habitual alcohol drinkers: A pilot study

Authors:
- Kenji Osaki
- Yoshio Shimizu
- Tetsuro Yamamoto
- Fumiharu Miyake
- Sumio Kondo
- Hideyo Yamaguchi
View Affiliations

Affiliations: Tokyo Branch, Bizen Chemical Co. Ltd., Tokyo 103‑0023, Japan, Okayama Head Office, Bizen Chemical Co. Ltd., Okayama 709‑0716, Japan, Research Center, TTC Co. Ltd., Tokyo 113‑0021, Japan, Product Formulation Division, Bizen Chemical Co. Ltd., Okayama 709‑0716, Japan, Medical Corporation Kenshokai, Fukushima Healthcare Center, Osaka 553‑0004, Japan
Published online on: June 10, 2015 https://doi.org/10.3892/etm.2015.2563
Pages: 705-710

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alcoholic liver disease (ALD) is characterized by elevated serum γ‑glutamyltransferase (GGT) activity with hepatic steatosis, hepatitis or occasionally fibrosis that may progress to cirrhosis. The potential therapeutic role of oyster extract (OE) or OE‑containing dietary supplements (OE supplement) in ALD has seldom been evaluated. In the present study, 84 adults who had an alcohol‑drinking habit and marginally high serum GGT levels were enrolled in a randomized, double‑blind, placebo‑controlled feeding trial to study the effect on alcohol‑impaired liver function as reflected by an increased serum level of GGT, as well as the safety, of an OE supplement. The subjects were randomized to receive either an OE supplement (OE group) or placebo (placebo group). There were 42 subjects (31 males and 11 females) in each group, and all the enrolled subjects entered the study. Four individuals (5%) dropped out for reasons unassociated with the study and 6 other subjects were excluded from the efficacy analysis because they did not maintain the required frequency of alcohol intake. As a result, 38 subjects in the placebo group and 36 in the OE group underwent efficacy assessment. Assays of GGT and other liver enzymes were performed at baseline (week 0) and at weeks 4, 8 and 12 of the intervention period. The mean serum levels of GGT in the placebo group gradually increased, while those in the OE group tended to decrease, although no significant within‑group differences were observed for either group. A significant between‑group difference in the change of mean GGT from baseline was, however, found at week 12 (P=0.049). No OE supplement‑associated untoward side‑effects nor any abnormal changes in routine laboratory tests and anthropometric parameters were observed throughout the 12‑week intervention. An OE supplement shows promise in reducing risk factors associated with ALD in adults with an alcohol intake habit.

View Figures

View References

1	Global status report on alcohol and health. World Health Organization; Geneva, Switzerland: 2011
2	Lu XL, Tao M, Luo JY, Geng Y, Zhao HL and Zhao P: Epidemiology of alcohol and liver disease. Zhonghua Gan Zang Bing Za Zhi. 6:467–468. 2002.(In Chinese).
3	Park SH, Kim CH, Kim DJ, et al: Prevalence of alcoholic liver disease among Korean adults: Results from the Fourth Korea National Health and Nutrition Examination Survey, 2009. Subst Use Misuse. 46:1755–1762. 2011. View Article : Google Scholar : PubMed/NCBI
4	Kim KA: Current status of liver diseases in Korea: toxic and alcoholic liver diseases. Korean J Hepatol. 15:(Sul 6). S29–S33. 2009. View Article : Google Scholar : PubMed/NCBI
5	Takada A and Tsutsumi M: National survey of alcoholic liver disease in Japan (1968–91). J Gastroenterol Hepatol. 10:509–516. 1995. View Article : Google Scholar : PubMed/NCBI
6	Horie Y, Ishii H and Hibi T: National survey of alcoholic liver disease in Japan. Nihon Arukoru Yakubutsu Igakkai Zasshi. 39:505–510. 2004.(In Japanese). PubMed/NCBI
7	Lucey MR, Mathurin P and Morgan TR: Alcoholic hepatitis. N Engl J Med. 360:2758–2769. 2009. View Article : Google Scholar : PubMed/NCBI
8	Pirmohamed M, Brown C, Owens L, Luke C, Gilmore IT, Breckenridge AM and Park BK: The burden of alcohol misuse on an inner-city general hospital. QJM. 93:291–295. 2000. View Article : Google Scholar : PubMed/NCBI
9	Pirmohamed M and Gilmore IT: Alcohol abuse and the burden on the NHS - time for action. J R Coll Physicians Lond. 34:161–162. 2000.PubMed/NCBI
10	Madhotra R and Gilmore IT: Recent developments in the treatment of alcoholic hepatitis. QJM. 96:391–400. 2003. View Article : Google Scholar : PubMed/NCBI
11	Barve A, Khan R, Marsano L, Ravindra KV and McClain C: Treatment of alcoholic liver disease. Ann Hepatol. 7:5–15. 2008.PubMed/NCBI
12	Huxtable RJ: Physiological actions of taurine. Physiol Rev. 72:101–163. 1992.PubMed/NCBI
13	Chen X, Sebastian BM, Tang H, McMullen MM, Axhemi A, Jacobsen DW and Nagy LE: Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats. Hepatology. 49:1554–1562. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kerai MD, Waterfield CJ, Kenyon SH, Asker DS and Timbrell JA: Taurine: Protective properties against ethanol-induced hepatic steatosis and lipid peroxidation during chronic ethanol consumption in rats. Amino Acids. 15:53–76. 1998. View Article : Google Scholar : PubMed/NCBI
15	Wu G, Yang J, Sun C, Luan X, Shi J and Hu J: Effect of taurine on alcoholic liver disease in rats. Amino Acids. 36:457–464. 2009. View Article : Google Scholar : PubMed/NCBI
16	Chang YY, Chou CH, Chiu CH, Yang KT, Lin YL, Weng WL and Chen YC: Preventive effects of taurine on development of hepatic steatosis induced by a high fat/cholesterol dietary habit. J Agric Food Chem. 59:450–457. 2011. View Article : Google Scholar : PubMed/NCBI
17	Harada S, Misawa S, Agarwal DP and Goedde HW: Liver alcohol dehydrogenase and aldehyde dehydrogenase in the Japanese: Isozyme variation and its possible role in alcohol intoxication. Am J Hum Genet. 32:8–15. 1980.PubMed/NCBI
18	Goedde HW, Agarwal DP, Harada S, Meier-Tackmann D, Ruofu D, Bienzle U, Kroeger A and Hussein L: Population genetic studies on aldehyde dehydrogenase isozyme deficiency and alcohol sensitivity. Am J Hum Genet. 35:769–772. 1983.PubMed/NCBI
19	Matsuda Y, Tsuchishima M, Ueshima Y, Takase S and Takada A: The relationship between the development of alcoholic liver and pancreatic diseases and the induction of gamma glutamyl transferase. Alcohol Alcohol Suppl. 1B:27–33. 1993.PubMed/NCBI
20	Conigrave KM, Davies P, Haber P and Whitfield JB: Traditional markers of excessive alcohol use. Addiction. 98:(Suppl 2). 31–43. 2003. View Article : Google Scholar : PubMed/NCBI
21	Matsuka Y, Wang D-H, Suganuma N, Imai K, Ikeda S, Taketa K and Kira S: Differential responses of serum gamma-glutamyltransferase to alcohol intake in Japanese males. Acta Med Okayama. 57:171–178. 2003.PubMed/NCBI
22	Bell H and Steensland H: Serum activity of gamma-glutamyltranspeptidase (GGT) in relation to estimated alcohol consumption and questionnaires in alcohol dependence syndrome. Br J Addict. 82:1021–1026. 1987. View Article : Google Scholar : PubMed/NCBI
23	Steffensen FH, Sørensen HT, Brock A, Vilstrup H and Lauritzen T: Alcohol consumption and serum liver-derived enzymes in a Danish population aged 30–50 years. Int J Epidemiol. 26:92–99. 1997. View Article : Google Scholar : PubMed/NCBI
24	Anton RF, Lieber C and Tabakoff B: CDTect Study Group: Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: Results from a multisite study. Alcohol Clin Exp Res. 26:1215–1222. 2002. View Article : Google Scholar : PubMed/NCBI
25	Lakshman MR: Some novel insights into the pathogenesis of alcoholic steatosis. Alcohol. 34:45–48. 2004. View Article : Google Scholar : PubMed/NCBI
26	Zhang C, Li X, Jing X, Zhang B, Zhang Q, Niu Q, Wang J and Tian Z: Protective effects of oyster extract against hepatic tissue injury in alcoholic liver diseases. J Ocean Univ China. 13:262–270. 2014. View Article : Google Scholar
27	Fujisawa H, Takehara I, Nishihori Y, Yano Y, Yamazaki N, Matsui H, Matsuda Y and Fukuhara I: Effect of 12 weeks ingestion of oyster extract on hepatic function in human volunteers with mild alcoholic liver damage. Trace Nutr Res. 29:13–17. 2012.(In Japanese).
28	Matsuda Y, Izuta S, Fujita T, Ohta T, Nakatsuka M, Yoshino M and Shibata Y: Influence of oyster extract administration of diabetes mellitus and hepatitis patients. Trace Nutr Res. 12:91–97. 1995.(In Japanese).
29	Ming Z, Shimizu Y, Furuta K, Tanaka S and Gohda E: Acceleration of alcohol metabolism by Crassostera gigas extract. Jpn Pharmacol Ther. 41:319–321. 2013.(In Japanese).
30	Devi SL, Viswanathan P and Anuradha CV: Regression of liver fibrosis by taurine in rats fed alcohol: Effects on collagen accumulation, selected cytokines and stellate cell activation. Eur J Pharmacol. 647:161–170. 2010. View Article : Google Scholar : PubMed/NCBI
31	Yang L, Latchoumycandane C, McMullen MR, Pratt BT, Zhang R, Papouchado BG, Nagy LE, Feldstein AE and McIntyre TM: Chronic alcohol exposure increases circulating bioactive oxidized phospholipids. J Biol Chem. 285:22211–22220. 2010. View Article : Google Scholar : PubMed/NCBI
32	Latchoumycandane C, Nagy LE and McIntyre TM: Chronic ethanol ingestion induces oxidative kidney injury through taurine-inhibitable inflammation. Free Radic Biol Med. 69:403–416. 2014. View Article : Google Scholar : PubMed/NCBI
33	Tanaka K, Nishizono S, Kugino K, Tamari M, Kurumiya M, Abe N and Ikeda I: Effects of dietary oyster extract on lipid metabolism, blood pressure and blood glucose in SD rats, hypertensive rats and diabetic rats. Biosci Biotechnol Biochem. 70:462–470. 2006. View Article : Google Scholar : PubMed/NCBI
34	Yoshikawa T, Naito Y, Masui K, Fujii T, Boku Y, Nakagawa S, Yoshida N and Kondo M: Free radical-scavenging activity of Crassostera gigas extract (JCOE). Biomed Pharmacother. 51:328–332. 1997. View Article : Google Scholar : PubMed/NCBI
35	Nishihori Y, Suzuki Y, Kishinami M, Fujisawa H, Nagaoka S, Yamazaki N, Matsui H and Matsuda Y: Study of safety and functionality in oyster extract powder. Trace Nutr Res. 28:40–44. 2011.
36	Wójcik OP, Koenig KL, Zeleniuch-Jacquotte A, Costa M and Chen Y: The potential protective effects of taurine on coronary heart disease. Atherosclerosis. 208:19–25. 2010. View Article : Google Scholar : PubMed/NCBI
37	Chesney RW: Taurine: Its biological role and clinical implications. Adv Pediatr. 32:1–42. 1985.PubMed/NCBI